Get started
Innate Pharma SA Class AInnate Pharma SA Class AInnate Pharma SA Class A

Innate Pharma SA Class A

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

IDD chart


Full chart

IDD upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪163.32 M‬ EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.610 EUR
Net income (FY)
‪−49.47 M‬ EUR
Revenue (FY)
‪12.62 M‬ EUR
Shares float
‪56.75 M‬
Beta (1Y)
0.68

Employees


Employees (FY)
181
Change (1Y)
+2 +1.12%
Revenue / Employee (1Y)
‪69.73 K‬ EUR
Net income / Employee (1Y)
‪−273.32 K‬ EUR

About Innate Pharma SA Class A


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Jonathan Dickinson
Website
innate-pharma.com
Headquarters
Marseille
Founded
1999
ISIN
FR0010331421
FIGI
BBG000Q71CT6
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. Its product pipeline includes Lacutamab, Monalizumab, Avdoralimab, and IPH62. The company was founded by Hervé Eloi Dominique Brailly, Eric Vivier, Marc Bonneville, Alessandro Moretta, Jean-Jacques Fournié, and François Romagné on September 23, 1999 and is headquartered in Marseille, France.

Check out other big names from the same industry as IDD.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

IDD news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of IDD is 1.746 EUR — it has increased by 2.11% in the past 24 hours. Watch Innate Pharma SA Class A stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Innate Pharma SA Class A stocks are traded under the ticker IDD.
IDD stock has fallen by −5.42% compared to the previous week, the month change is a −5.21% fall, over the last year Innate Pharma SA Class A has showed a −18.03% decrease.
We've gathered analysts' opinions on Innate Pharma SA Class A future price: according to them, IDD price has a max estimate of 6.92 EUR and a min estimate of 5.70 EUR. Watch IDD chart and read a more detailed Innate Pharma SA Class A stock forecast: see what analysts think of Innate Pharma SA Class A and suggest that you do with its stocks.
IDD reached its all-time high on Apr 27, 2015 with the price of 17.688 EUR, and its all-time low was 1.050 EUR and was reached on Mar 6, 2009. View more price dynamics on IDD chart.
See other stocks reaching their highest and lowest prices.
IDD stock is 2.06% volatile and has beta coefficient of 0.68. Track Innate Pharma SA Class A stock price on the chart and check out the list of the most volatile stocks — is Innate Pharma SA Class A there?
Today Innate Pharma SA Class A has the market capitalization of ‪163.32 M‬, it has decreased by −0.22% over the last week.
Yes, you can track Innate Pharma SA Class A financials in yearly and quarterly reports right on TradingView.
Innate Pharma SA Class A is going to release the next earnings report on Sep 17, 2025. Keep track of upcoming events with our Earnings Calendar.
IDD earnings for the last half-year are −0.31 EUR per share, whereas the estimation was −0.26 EUR, resulting in a −21.57% surprise. The estimated earnings for the next half-year are −0.28 EUR per share. See more details about Innate Pharma SA Class A earnings.
Innate Pharma SA Class A revenue for the last half-year amounts to ‪7.78 M‬ EUR, despite the estimated figure of ‪17.32 M‬ EUR. In the next half-year revenue is expected to reach ‪12.00 M‬ EUR.
IDD net income for the last half-year is ‪−24.71 M‬ EUR, while the previous report showed ‪−24.76 M‬ EUR of net income which accounts for 0.23% change. Track more Innate Pharma SA Class A financial stats to get the full picture.
No, IDD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 10, 2025, the company has 181 employees. See our rating of the largest employees — is Innate Pharma SA Class A on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Innate Pharma SA Class A EBITDA is ‪−57.09 M‬ EUR, and current EBITDA margin is −452.47%. See more stats in Innate Pharma SA Class A financial statements.
Like other stocks, IDD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Innate Pharma SA Class A stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Innate Pharma SA Class A technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Innate Pharma SA Class A stock shows the sell signal. See more of Innate Pharma SA Class A technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.